Recovery Protocol Updates: An International Consensus Read

Recovery, in cellular therapy, is the part nobody quite knows how to publish about. The infusion makes the press release; the seventy-two hours that follow rarely do. Yet the international working groups have, over the past eighteen months, been quietly redrafting what those hours should look like — and the 2026 consensus papers, circulated in advisory form between ISCT, ISSCR and several regional regenerative-medicine societies, read less like a revolution than a series of careful refinements. One arrives at the documents expecting a manifesto. What one finds instead is a tier of patient-care suggestions — measured, hedged, and rather more hospitable to clinical reality than the headlines suggest. 呢啲文件其實幾耐人尋味, a Seoul-based regenerative physician told me last month over yum cha at Lee Garden Three. He wasn't being dramatic. He rarely is.

What the 2026 consensus drafts are — and what they are not

The 2026 international consensus drafts on cellular therapy recovery are working-group recommendations — not regulation, not law, not a binding standard of care. They emerge from a familiar lattice of professional bodies: the International Society for Cell & Gene Therapy (ISCT), the International Society for Stem Cell Research (ISSCR), and a constellation of regional regenerative-medicine societies that have, in the past two years, begun to coordinate more visibly on aftercare. The documents do not claim novelty. They claim coherence — a synthesis of post-infusion observation periods, immunomodulation timelines, and patient-reported outcome frameworks that had, until recently, varied considerably between Seoul, Tokyo, Zurich, and the gulf clinics. What recommends this round of drafts is not the radical content but the institutional appetite for harmonisation. Clinicians one speaks to in Gangnam describe the tone as cautious; one suspects the working groups intended exactly that.

The seventy-two-hour window — and why it has been formalised

The seventy-two-hour post-infusion window refers to the observation and stabilisation period during which the consensus drafts now suggest patients remain within reach of their treating clinic. This is not new — most reputable Korean cellular therapy programmes have informally observed something close to a three-day window for years — but the 2026 drafts formalise the language and, more interestingly, the rationale. The reasoning offered is two-fold. First, immunomodulatory effects of allogeneic mesenchymal stromal cell infusions appear to peak within this window in the studies the working groups have chosen to cite. Second, transient adverse events — low-grade pyrexia, mild fatigue, the occasional flushing reaction — tend to resolve, when they appear at all, inside the same period. The drafts are careful here. They do not claim the seventy-two-hour window is sufficient; they claim it is the minimum that current evidence supports. The distinction matters. A clinician at one of the better-known Apgujeong clinics described it to me as ‘a floor, not a ceiling,’ which seems about right. Patients report finding the formalisation reassuring — there is something in the act of naming a window that calms the otherwise unstructured anxiety of post-treatment days.

Hospitality, infrastructure, and the recovery suite question

A recovery suite, in the Korean cellular-therapy context, is a clinic-adjacent or clinic-internal room — typically marble-floored, low-lit, equipped for short observation rather than overnight inpatient stay — where patients may rest in the immediate post-infusion hours. The 2026 consensus drafts do not specify hospitality standards; they cannot, and should not. What they do specify, with some care, is that the post-infusion environment should permit clinical observation, temperature monitoring, and rapid escalation should an adverse event present. The Korean clinics one tends to recommend have rather quietly built infrastructure that exceeds these requirements — recovery lounges that resemble the lobby of the Mandarin Oriental more than a hospital ward, with concierge-style nursing and the discreet availability of a treating physician within minutes. This is, on first impression, a hospitality flourish. It is also, on second reading, exactly what the consensus drafts are gesturing toward without quite saying so. One Gangnam medical director — a woman whose practice has been quietly setting standards for the better part of a decade — put it this way: ‘The room must be calm enough for the patient to rest, and serious enough for the clinician to work.’ The consensus drafts, in their bureaucratic register, are saying the same thing.

What the drafts say about activity, travel, and the international patient

The international patient, in cellular-therapy literature, is the patient whose treatment, accommodation, and home jurisdiction sit in three different countries — and whose recovery logistics therefore require a hospitality framework the drafts have only recently begun to address. This is the section of the 2026 papers that interests Hong Kong readers most directly, and it is, predictably, the most hedged. The working groups recommend — they are careful with the verb — that international patients consider remaining in the treatment city for at least seven days post-infusion before undertaking long-haul travel. The reasoning is partly clinical (delayed-onset reactions, however rare, are more easily managed near the treating clinic) and partly logistical (the seventy-two-hour window plus a buffer for follow-up consultation). The drafts do not prohibit earlier travel; they note that earlier travel ‘should be discussed with the treating physician,’ which is the consensus-document register for ‘proceed with care.’ For a patient flying in from Causeway Bay, this often means restructuring the trip — a longer stay in a serviced apartment near the clinic, a quieter itinerary, perhaps a pre-booked room at one of the wellness-oriented hotels in Cheongdam. The clinics worth considering tend to assist with this; the ones worth avoiding leave it to the patient. One learns to tell.

Patient-reported outcomes — and the quiet emphasis on hedged language

Patient-reported outcomes, in this context, are the structured self-assessments — energy, sleep, mood, perceived recovery — that patients log in the days and weeks following infusion. The 2026 drafts give them more space than previous iterations did. This is, quietly, the most editorially interesting development in the documents. The working groups acknowledge what experienced clinicians have long observed: that the subjective recovery experience does not always track the biochemical one, and that patient-reported outcomes are therefore both useful and, on their own, insufficient. The drafts recommend a structured collection protocol — typically a brief daily log for the first two weeks, tapering to weekly thereafter — and they recommend, with admirable restraint, that patients be told their reports are one input among several. The hedging language is striking. Patients ‘may experience’ a graded improvement; benefits ‘have been associated with’ certain protocols; outcomes ‘may vary’ with patient-specific factors that are listed at length. A reader from a luxury-magazine background recognises the register immediately — it is the prose of careful editorial responsibility, applied to medicine. One rather approves.

How the Korean clinics one tends to recommend are responding

The clinics one tends to recommend in Gangnam — the Apgujeong-Cheongdam corridor where most credible cellular-therapy practice is concentrated — have, by and large, been moving toward consensus-aligned protocols for some time. What the 2026 drafts have done is provide them with a vocabulary. Aftercare check-ins, formerly an internal courtesy, are now described as ‘structured patient-reported outcome collection.’ The recovery lounge, formerly a hospitality flourish, is now ‘consensus-aligned post-infusion observation infrastructure.’ The seventy-two-hour window, formerly an in-house convention, is now ‘alignment with international working-group recommendations.’ This may read as cynical — and one is, by training, slightly cynical — but it reflects something genuine. The clinics whose practice was always careful are now able to describe their care in language that travels across jurisdictions. For a Hong Kong patient flying in for a single procedure, this matters. It matters less for the procedure itself than for the recovery — for the seventy-two hours one tends not to think about until they are happening. A friend who completed a course of treatment in Apgujeong in March said, simply: ‘The room knew what it was doing.’ One suspects the consensus drafts would consider that a fair summary of their intent.

What remains unresolved — and what the next round of drafts may address

Unresolved questions, in any consensus document, are the questions the working groups have agreed not to settle yet. The 2026 drafts leave several open, and their candour about doing so is, on reflection, one of the documents’ better qualities. Long-term outcome tracking beyond twelve months remains under-specified — the working groups acknowledge that the data infrastructure for two-year and five-year follow-up is uneven across jurisdictions, and they decline to mandate what cannot yet be uniformly delivered. Cell-source standardisation, particularly for allogeneic preparations, remains a topic the drafts gesture at without resolving. Cross-border data portability — the question of whether a patient’s outcome log in Seoul can be meaningfully read by a clinician in Hong Kong — receives a paragraph that reads, charitably, as a placeholder for future work. The next round of drafts, expected in late 2027, is rumoured to take up these questions in earnest. One reads the current documents, then, as a careful interim — a tier of recommendations that improve on what came before, hedge appropriately on what is not yet known, and leave room for the field to mature into them. That is, perhaps, the most one can ask of a consensus document. It is also, in a refined way, rather more than the field has had until now.

“The room must be calm enough for the patient to rest, and serious enough for the clinician to work.”

A Gangnam medical director, on what a recovery suite is for

Frequently asked questions

Are the 2026 international consensus drafts legally binding?

No. The drafts are working-group recommendations issued by professional bodies such as ISCT and ISSCR; they carry editorial weight rather than regulatory force. Patients should expect reputable Korean clinics to align with them voluntarily, but the legal standard of care in each jurisdiction continues to be set by national regulators.

Why is the seventy-two-hour window now formalised?

The working groups concluded that current evidence supports seventy-two hours as the minimum observation period during which immunomodulatory effects peak and transient adverse events typically resolve. The drafts describe it as a floor, not a ceiling — patients with specific risk factors may be advised to remain longer, at the treating physician’s discretion.

Should an international patient travel home immediately after a cellular therapy infusion?

The drafts recommend, in hedged language, that international patients consider remaining in the treatment city for at least seven days post-infusion before long-haul travel. Earlier travel is not prohibited; it is meant to be discussed with the treating physician, with the seventy-two-hour observation window respected as a minimum.

What should a patient look for in a recovery suite or lounge?

The consensus drafts emphasise clinical observation capacity — temperature monitoring, nursing presence, and rapid physician access — rather than hospitality standards. That said, an environment calm enough to rest in, and serious enough to be clinically useful, is what the better Gangnam clinics tend to provide. Marble floors are optional; clinical seriousness is not.

Are patient-reported outcomes considered reliable?

The drafts treat patient-reported outcomes as one input among several. They are useful for capturing the subjective recovery experience — energy, sleep, mood — but the working groups are careful to note that subjective improvement does not always track biochemical markers. Patients may be asked to log outcomes daily for the first two weeks, then weekly thereafter.

What questions does the 2026 consensus leave open?

Long-term outcome tracking beyond twelve months, cell-source standardisation for allogeneic preparations, and cross-border data portability all remain under-specified. The next round of drafts, expected in late 2027, is anticipated to address these questions more directly.

How can a patient tell whether a clinic genuinely follows the consensus drafts?

One looks for structured aftercare protocols — daily check-ins, written outcome logs, a named coordinator for the recovery period — and for a clinic willing to discuss its observation infrastructure in clinical rather than marketing terms. The clinics worth considering tend to assist with travel restructuring; the ones worth avoiding leave logistics entirely to the patient.